NVO Stock: Why Morgan Stanley Is Bearish On Novo Nordisk Despite Its Weight-Loss Drug Opportunity
Morgan Stanley downgraded Novo to ‘Underweight’ from ‘Equal Weight’ while keeping its $40 price target, a 7% downside from current levels. The firm cited “subdued” mid-term growth, a relatively demanding valuation, and a significant loss-of-exclusivity risk after 2030 for the downgrade. Morgan Stanley said Semaglutide, which accounts for roughly 75% of Novo’s sales in 2026, … Read more